Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

NHS Trust Focuses On Staff Health
Hydration expert, Water Wellpoint is playing a key role in helping public sector employers look after the health and wellbeing of their staff. The company has recently been working with East London NHS Foundation Trust to run a series of wellbeing days, giving employees the ability to check key aspects of their health in a total voluntary format.
generic viagra online
Stem Cell Therapeutics Corp. Announces Publication Of Phase I Stroke Data
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) is pleased to announce the acceptance and publication of the paper entitled "Open labeled, uncontrolled pharmacokinetic study of single intramuscular hCG dose in healthy male volunteers" by the International Journal of Clinical Pharmacology and Therapeutics, Vol. 47, August 2009. This paper was authored by Drs. Alan Moore, President & CEO, Allen Davidoff, VP Product Development and Yan Yang, Clinical Research Associate, all of SCT; Dr. Michael D. Hill of Foothills Hospital at the University of Calgary, and Dr. Steven C. Cramer, from the University of California, Irvine.
News of the day
Moist Wound Healing Reduces Scarring And Promotes Faster Healing
New consensus has been reached by a panel of leading European experts on the guidelines for the treatment of acute minor wounds which states that healing is accelerated by a moist wound environment.
Health Insurance

Atrium Medical Receives CE Mark For Its CinatraTM CoCr Coronary Stent System

Atrium Medical is pleased to announce that is has received CE Mark for a new generation Cobalt Chromium Coronary Stent System called Cinatra™. Cinatra™ is indicated for the treatment of coronary artery occlusive disease. Atrium is excited to release this best in class Cobalt Chromium Coronary Stent System that is extremely low in profile, ultra flexible, and highly deliverable. In an independent lab test, Atrium"s new Cinatra™ CoCr Stent was highlighted as having the lowest crossing profile and greatest flexibility when compared to the leading competitors.* The advanced design of the Cinatra™ CoCr Stent with its superior mechanical properties have produced excellent clinical results yielding a very low late lumen loss. Preliminary results from the CONFIRM 1 multi-center prospective trial have shown the Cinatra™ CoCr Stent to have a mean in-stent late lumen loss of 0.69 mm at 6 months. This low late lumen loss is clear evidence that Cinatra™ offers excellent clinical results and will offer cardiologists a new option when treating coronary artery disease. *Data on file at Atrium. Atrium


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009